CYTOKINETICS' CANCER TRIAL FAILS

A A

Cytokinetics has reported that a clinical trial of ispinesib, an experimental lung cancer treatment, has failed.

The company reported that the Phase II trial, run by GlaxoSmithKline, failed to meet the criteria to advance to the next stage of clinical testing. The drug had been given to patients with platinum-sensitive non-small cell lung cancer.